Community Clinical Oncology Program

放射治疗肿瘤学小组（RTOG）社区临床肿瘤学计划（CCOP）的独特之处在于，它是唯一一个专注于提供放射（RT）相关症状改善试验的CCOP，并为CCOP社区带来最先进的RT治疗试验。RTOG CCOP进行的试验只能在特定的RT组中完成，例如评估缓解疼痛性骨转移的不同分割时间表，使用立体定向放射外科手术缓解脊柱转移，以及使用海马回避与RT治疗计划，以最大限度地减少脑转移全脑RT后的记忆丧失。为了实现我们独特的使命，我们已经制定了重大的战略变化，包括新的PI领导;对当前资助期内概念开发和患者累积的促进者和障碍进行了长期评估;修订了委员会结构，包括新的指导/概念审查委员会，以加强科学，增加我们的投资组合，并进一步吸引CCOP并提高累积。目标包括：1）提供癌症控制研究计划，以研究预防或管理症状的干预措施，并研究有助于早期预测结果的生物措施。这一目标集中在对接受RT治疗的患者重要的4个研究主题上：粘膜炎和上皮损伤的保护剂;神经认知;姑息和QoL;以及迟发效应和存活率。2)通过RTOG向CCOP成员提供完整的临床和翻译协议，以及3）维护基础设施和工具，以进行和评估RTOG癌症控制研究的影响。CCOP利用其NCI资金，通过与RTOG开发共享资源，包括转化研究计划，可行性审查和临床试验，教育和招募工作组，来帮助支持这些目标。我们过去的工作，新的愿景和战略变化将推进症状管理科学，并为干预措施提供证据，最终提高RT治疗癌症患者的生存质量。

The Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP) is unique in that it is the only CCOP focused solely on providing radiation (RT)-related symptom amelioration trials, as well as bringing state-of-the-art RT treatment trials to the CCOP community. The RTOG CCOP conducts trials that can only be accomplished in a RT specific group, such assessment of different fractionation schedules for the palliation of painful bone metastases, the use of stereotactic radiosurgery to palliate spinal metastases, and the use of hippocampal avoidance with RT treatment planning to minimize memory loss after whole brain RT for brain metastases. To meet our unique mission we have instituted significant strategic changes including new PI leadership; a lengthy evaluation of facilitators and barriers to concept development and patient accrual over the current grant period; a revised committee structure including a new Steering/Concept Review Committee to strengthen the science, increase our portfolio, and further engage the CCOPs and improve accrual. Objectives include: 1) provision of a cancer control research program to study interventions to prevent or manage symptoms, and the study of biological measures that will assist in earlier prediction of outcomes. This aim is focused on 4 research themes important to patients treated with RT: Protectants for Mucositis & Epithelial Injury; Neurocognition; Palliation & QoL; and Late Effects & Survivorship. 2) Provision of access to the full complement of clinical and translational protocols available through the RTOG to CCOP members, and 3) maintenance of an infrastructure and tools for conduct and assessment of the impact of RTOG cancer control studies. The CCOP has leveraged its NCI funding to help support these objectives by developing shared resources with the RTOG including a Translational Research Program, a Feasibility Review and Clinical Trials, Education and Recruitment Working Groups. Our past work, new vision and strategic changes will advance symptom management science and provide evidence for interventions that will ultimately improve the quality of survival for patients with cancer treated with RT.